Highlights Collegium Pharmaceutical, Inc.

Equities

COLL

US19459J1043

Market Closed - Nasdaq Other stock markets 04:00:00 2024-07-12 pm EDT			5-day change	1st Jan Change
31.78 ^USD	-0.31%		-1.24%	+3.25%

Jul. 01	Collegium Pharmaceutical, Inc.(NasdaqGS:COLL) added to Russell 2000 Growth-Defensive Index	CI
Jul. 01	Collegium Pharmaceutical, Inc.(NasdaqGS:COLL) added to Russell 2000 Defensive Index	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Collegium Pharmaceutical Says Nucynta Gets FDA Pediatric Exclusivity	Jun. 13	MT
Collegium Pharmaceutical, Inc. Obtains Six Month Extension of U.S. Pediatric Exclusivity for Nucynta Franchise	Jun. 13	CI
Collegium Pharmaceutical Launches $35 Million Accelerated Share Repurchase Program	May. 13	MT
Collegium Pharmaceutical Q1 Adjusted Net Income, Revenue Rise; 2024 Outlook Reiterated	May. 10	MT
Earnings Flash (COLL) COLLEGIUM PHARMACEUTICAL Posts Q1 EPS $1.45, vs. Street Est of $1.47	May. 09	MT
Collegium Pharmaceutical, Inc. Reaffirms Earnings Guidance for the Full Year 2024	May. 09	CI
Tranche Update on Collegium Pharmaceutical, Inc.'s Equity Buyback Plan announced on January 3, 2024.	May. 09	CI
Collegium Pharmaceutical, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 08	CI
Collegium Announces Authorized Generic Agreement with Hikma Pharmaceuticals USA Inc. for Nucynta® and Nucynta® ER	Apr. 29	CI
Collegium Pharmaceutical to Redeem $26.35 Million of Senior Notes	Apr. 11	MT
Ligand Pharmaceuticals Appoints Scott Plesha to the Role of Chief Executive Officer for Pelthos Therapeutics	Apr. 03	CI
Collegium Pharmaceutical's Q4 Adjusted Earnings, Revenue Increase	Feb. 23	MT
Earnings Flash (COLL) COLLEGIUM PHARMACEUTICAL Reports Q4 EPS $1.58, vs. Street Est of $1.26	Feb. 22	MT
Collegium Pharmaceutical, Inc. Reaffirms Earnings Guidance for the Full Year 2024	Feb. 22	CI
Collegium Pharmaceutical, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 22	CI
Collegium Pharmaceutical, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 22	CI
Collegium Pharmaceutical Expects Net Product Revenue of up to $595 Million in 2024	Jan. 03	MT
Tranche Update on Collegium Pharmaceutical, Inc.'s Equity Buyback Plan announced on January 4, 2023.	Jan. 03	CI
Collegium Pharmaceutical, Inc. announces an Equity Buyback for $150 million worth of its shares.	Jan. 03	CI
Collegium Pharmaceutical, Inc. Provides Earnings Guidance for the Year 2024	Jan. 03	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Collegium Pharmaceutical, Inc.

Equities

COLL

US19459J1043

Highlights

Filters